Emergent BioSolutions Q2 revenue up 66% to $234M, net loss $180M on $191M impairment; restructuring cuts 93 jobs

Emergent BioSolutions Inc.

Q2 total revenues $234.3M (+66% YoY); adjusted net income $30.9M (+134% YoY); GAAP net loss $180.2M due to $191.3M non-cash impairment on NARCAN asset group.
Restructuring plan: cut ~93 employees, close Gaithersburg wet labs; expected annualized savings ~$40M, charges $10M-$11.5M in H2 2026.
Simon Lowry (CMO, Head of R&D) departing Aug 19; Stephanie Duatschek named EVP, Chief Growth Officer.
Naloxone revenue down 22% to $52.4M; Smallpox MCM up 150% to $101.6M; Other Products (BAT) up to $54.1M.

item 2.02 item 2.05 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.